Your browser doesn't support javascript.
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers.
Basci, Semih; Ata, Naim; Altuntas, Fevzi; Yigenoglu, Tugçe Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, Sinem; Bastürk, Abdülkadir; Hacibekiroglu, Tuba; Dogu, Mehmet Hilmi; Berber, Ilhami; Dal, Kürsat; Erkurt, Mehmet Ali; Turgut, Burhan; Çelik, Osman; Ülgü, Mustafa Mahir; Birinci, Suayip.
  • Basci S; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey. dr.semihbasci@gmail.com.
  • Ata N; Department of Strategy Development, Republic of Turkey, Ministry of Health, Ankara, Turkey.
  • Altuntas F; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Yigenoglu TN; Department of Hematology, School of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey.
  • Dal MS; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Korkmaz S; Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Namdaroglu S; Department of Hematology, Kayseri City Hospital, Kayseri, Turkey.
  • Bastürk A; Department of Hematology, Bozyaka Training and Research Hospital, Izmir, Turkey.
  • Hacibekiroglu T; Department of Hematology, School of Medicine, Selçuk University, Konya, Turkey.
  • Dogu MH; Department of Hematology, School of Medicine, Sakarya University, Sakarya, Turkey.
  • Berber I; Department of Hematology, Istanbul Training and Research Hospital, Istanbul, Turkey.
  • Dal K; Department Hematology, School of Medicine, Inönü University, Malatya, Turkey.
  • Erkurt MA; Department of Internal Medicine, Keçiören Training and Research Hospital, Ankara, Turkey.
  • Turgut B; Department Hematology, School of Medicine, Inönü University, Malatya, Turkey.
  • Çelik O; Department of Hematology, School of Medicine, Namik Kemal University, Tekirdag, Turkey.
  • Ülgü MM; Public Hospitals General Directorate, Ministry of Health, Republic of Turkey, Ankara, Turkey.
  • Birinci S; General Directorate of Health Information Systems, Ministry of Health, Republic of Turkey, Ankara, Turkey.
Intern Emerg Med ; 17(1): 135-139, 2022 01.
Article in English | MEDLINE | ID: covidwho-1263175
ABSTRACT
Previous studies reported that COVID-19 patients with cancer had higher rates of severe events such as intensive care unit (ICU) admission, mechanical ventilation (MV) assistance, and death during the COVID-19 course compared to the general population. However, no randomized study compared the clinical course of COVID-19 in patients with hematologic cancers to patients with solid cancers. Thus, in this study, we intend to reveal the outcome of COVID-19 in hematologic cancer patients and compare their outcomes with COVID-19 patients with solid cancers. The data of 926 laboratory-confirmed COVID-19 patients, including 463 hematologic cancer patients and an age-gender paired cohort of 463 solid cancer patients, were investigated retrospectively. The frequencies of severe and critical disease, hospital and ICU admission, MV assistance were significantly higher in hematologic cancer patients compared with the solid cancer patients (p = 0.001, p = 0.045, p = 0.001, and p = 0.001, respectively). The hospital stay was longer in patients with hematologic cancers (p = 0.001); however, the median ICU stay was 6 days in both groups. The case fatality rate (CFR) was 14.9% in patients with hematologic cancers, and it was 4.8% in patients with solid cancers, and there was a statistically significant difference regarding CFR between groups (p = 0.001). Our study revealed that COVID-19 patients with hematologic cancers have a more aggressive course of COVID-19 and have higher CFR compared to COVID-19 patients with solid cancers and support the increased susceptibility of patients with hematologic cancers during the outbreak.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Intern Emerg Med Journal subject: Emergency Medicine / Internal Medicine Year: 2022 Document Type: Article Affiliation country: S11739-021-02784-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Intern Emerg Med Journal subject: Emergency Medicine / Internal Medicine Year: 2022 Document Type: Article Affiliation country: S11739-021-02784-y